Xilam: 2017 Full-Year Revenue: EUR 24.4 million, up 54%
Regulatory News:
Xilam (Paris:XIL) is announcing consolidated 2017 revenue of EUR 24.4 million, an increase of 54%. This performance is all the more impressive on the back of 40% growth in 2016.
In EUR 000 | 31.12.2017 (1) | 31.12.2016 | Change | |||
New productions(2) | 15,319 | 10,756 | 42% | |||
Catalogue | 9,017 | 5,083 | 77% | |||
Other | 62 | 39 | 59% | |||
Revenue | 24,398 | 15,878 | 54% | |||
(1)
unaudited data
(2)
including subsidies and development
New productions: substantial progress in volume terms, very strong value growth
In 2017, Xilam delivered 63 half-hour programmes to broadcasters, compared to 51 in 2016. This volume growth of 24% demonstrates the Group’s ability to satisfy strong market demand.
With revenue of EUR 15.3 million, this growth represents a 42% increase in value terms. This solid growth is a testament to the quality of the new programmes offered by Xilam and the company’s ability to build the value of its new content. Digital platforms and television channels are now both behind the sharp rise in sales of new productions.
Catalogue: performance improving on all platforms
Catalogue revenue exceeded EUR 9 million in 2017, which is an increase of 77% compared to last year. As such, Xilam’s Catalogue division has passed another major milestone which attests to the long-term strength of its brands.
This record performance is the result of more intense competition between traditional (paid and free) TV channels and digital platforms, in which Xilam has a very strong foothold. Digital platforms now account for 40% of Catalogue revenue and 23% of total revenue.
Finally, Xilam’s YouTube catalogue garnered over 2.6 billion views in 2017, which is a 21% increase compared to last year. This growth was primarily buoyed by the global success of the Zig & Sharko series which, alongside Oggy & the Cockroaches, has become a new driver for the Group’s catalogue.
An ever-increasing international presence
Xilam’s revenue growth is also due to the extremely sharp increase in international sales, which now account for 56% of total revenue. Standing at EUR 13.8 million, international sales increased 80% compared to last year.
On the Catalogue segment, international revenue accounted for 89% of revenue in 2017. Thanks to their ability to broadcast worldwide simultaneously, digital platforms are making a major contribution to international sales growth.
Outlook for 2018: continued growth
Stepping up the pace of premium content deliveries
Xilam is now perfectly sized in terms of resources and talent to satisfy the sharp growth expected. In 2018, Xilam’s teams will be focused on the production of seven animated series. In particular, Xilam will continue with deliveries of new seasons of Oggy & the Cockroaches, the wildlife series If I were an animal, Season 2 of Magic, and Paprika.
Xilam also has a number of new series currently in production, including:
- Mr. Magoo, which broke international pre-sale records that should lead to a very promising future;
- Coach me if you can, an original, football-themed creation from the Xilam studio that is expected to be released worldwide and will be launched to coincide with Euro 2020;
- Season 3 of Zig & Sharko, which has already been pre-purchased by clients that bought the previous seasons.
These series will enable Xilam to achieve its target of delivering over 70 half-hour programmes in 2018. This step-up in production is in line with the company's roadmap, which aims to deliver over 100 half-hour programmes in 2020.
Xilam’s four studios (Paris, Lyon, Angoulême and Ho-Chi-Minh City) are now fully operational and well prepared to meet this target.
Innovation and constant creativity
Other projects created in the Xilam studios will enter production in 2018.
These include The Fabulous Adventures of Prince Moka and Tiny Bad Wolf , two original creations that will afford Xilam additional growth avenues in the coming years.
New catalogue revenue streams
In 2017, Xilam announced that it had signed new merchandising contracts, such as those signed with Lansay (toys) and Nazara (mobile video games).
Additions to Xilam’s sales team and the set-up of an agent network covering 75% of the world will drive growth in this segment in 2018.
Chairman and CEO of Xilam, Marc du Pontavice, commented, “ Xilam is already the leader on the French market, and is gradually becoming one of the top-tier providers of premium content to the world’s major broadcasters and platforms. The relevance of the company’s investment strategy is evident; our catalogue is becoming stronger and stronger, with content that stimulates children’s imagination.”
About Xilam
Xilam is one of Europe’s leading animation companies, producing and distributing original children’s and family entertainment content in both 2D and 3D formats across TV, film and digital media platforms.
Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and 3 feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons, Rolling with the Ronks! and its first pre-school series, Paprika.
Broadcast in over 160 countries on all the major TV networks, these series are also breaking audience records on all the major digital platforms, including YouTube with over 2.6 billion views in 2017, ranking Xilam as one of the top global content providers in animation.
Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.
Xilam is listed on Euronext Paris / Ticker: XIL / ISIN code: FR0004034072
Xilam is eligible for the PEA-PME investment scheme.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201006121/en/
Contact information
Xilam
Marc du Pontavice – Chairman and CEO
François
Bardoux – CFO
Tel: (33) 01 40 18 72 00
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom